Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides

被引:23
作者
Anderson, RW
Kudelka, AP
Honda, T
Pollack, MS
Gershenson, DM
Gillogly, MA
Murray, JL
Ioannides, CG
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Med Oncol, Houston, TX 77030 USA
[4] Univ Texas, Hlth Sci Ctr, Dept Surg, Histocompatibil Lab, San Antonio, TX 78284 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
关键词
HER-2; proliferation; Th1; cryptic determinants;
D O I
10.1007/s002620000143
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunization with tumor antigens induces cellular and humoral immune responses. These responses by T cells are specific for defined epitopes (determinants) in the molecule of the immunizing tumor antigen. Extension of such responses to self-antigens requires induction of autoimmunity to the tumor. As with systems of autoimmune disease, expression of T cell autoimmunity is charaterized by diversification of responses from the inducer determinant to other responder (cryptic) determinants. Since similar strategies may be useful for therapy of human cancers, we investigated whether the induction of response to a HER-2 peptide F7 (776 789) induces enhanced reactivity of other HER-2 peptides. We found that stimulation with F7 can expand a response to another epitope F13 (884-899) in both an ovarian cancer patient with progressive disease and a healthy donor who shared HLA-DR11. This response was characterized mainly by increased interferon gamma secretion, and proliferation, but was not observed with another donor who shared HLA-DR14 and HLA-DQ5 with the patient. Since repeated vaccination with the same epitope may lead to a decline of primary cell reactivity caused by apoptosis spreading the response to other epitopes, the tumor antigen may provide an approach for maintaining an inflammatory Th1 response during cancer vaccination.
引用
收藏
页码:459 / 468
页数:10
相关论文
共 23 条
[1]   An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions [J].
Anichini, A ;
Molla, A ;
Mortarini, R ;
Tragni, G ;
Bersani, I ;
Di Nicola, M ;
Gianni, AM ;
Pilotti, S ;
Dunbar, R ;
Cerundolo, V ;
Parmiani, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (05) :651-667
[2]   Human tumor antigens recognized by T lymphocytes [J].
Boon, T ;
vanderBruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729
[3]   Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses in vivo [J].
delGuercio, MF ;
Alexander, J ;
Kubo, RT ;
Arrhenius, T ;
Maewal, A ;
Appella, E ;
Hoffman, SL ;
Jones, T ;
Valmori, D ;
Sakaguchi, K ;
Grey, HM ;
Sette, A .
VACCINE, 1997, 15 (04) :441-448
[4]  
Disis ML, 1999, CLIN CANCER RES, V5, P1289
[5]  
Fisk B, 1997, ANTICANCER RES, V17, P45
[6]  
IOANNIDES CG, 1992, MOL CARCINOGEN, V6, P77
[7]  
KAUFMAN DL, 1993, NATURE, P366
[8]  
LEHMANN PV, 1992, NATURE, V358, P156
[9]   Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells [J].
Marincola, FM ;
Rivoltini, L ;
Salgaller, ML ;
Player, T ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (04) :266-277
[10]  
MARSHALL KW, 1995, J IMMUNOL, V154, P5927